An Australian-designed vaccine that could allow coeliacs to safely consume gluten is entering the next trial phase following successful initial testing.
The vaccine Nexvax2 was designed in Melbourne and is based on years of research by Walter and Eliza Hall Institute of Medical Research, according to a Fairfax Media report.
The treatment aims to reprogram the immune system's abnormal toxic response to gluten, and the first trial took place in 2011, when the injection was found to be safe and well tolerated.
The next phase of trials will start at the Royal Melbourne Hospital Clinical Trials Centre, followed by Perth, Adelaide, Brisbane, Mackay and the Sunshine Coast.
